Financial Overview - FTAI Infrastructure reported a net loss attributable to stockholders of $79.816 million for Q2 2025, compared to a loss of $54.350 million in Q2 2024 [2][24] - The basic and diluted loss per share for common stock was $0.73 for Q2 2025, compared to a loss of $0.52 in the same quarter of the previous year [2][24] - Adjusted EBITDA for Q2 2025 was $45.916 million, an increase from $34.256 million in Q2 2024 [2][24] Dividend Declaration - The Board of Directors declared a cash dividend of $0.03 per share for the quarter ended June 30, 2025, payable on September 8, 2025 [3] Business Highlights - The company agreed to acquire the Wheeling & Lake Erie Railway for $1.05 billion [9] - Plans to refinance existing 10.50% senior notes and Series A preferred stock upon closing of the acquisition [9] - Closed financing of $300 million of tax-exempt debt at Repauno with average coupons of 6.50%, with construction of phase 2 infrastructure fully underway [9] Key Performance Measures - Adjusted EBITDA is utilized as the key performance measure by the Chief Operating Decision Maker, providing insights into operational performance and resource allocation [21][22] - The reconciliation of net loss attributable to stockholders to Adjusted EBITDA for Q2 2025 indicates significant adjustments for various expenses, including interest and depreciation [23][24] Financial Position - Total assets as of June 30, 2025, were $4.407 billion, up from $2.374 billion as of December 31, 2024 [16][17] - Current assets increased to $539.045 million from $219.851 million year-over-year [16] - Total liabilities rose to $3.631 billion from $1.918 billion as of December 31, 2024 [17] Cash Flow Analysis - Net cash used in operating activities for the six months ended June 30, 2025, was $90.872 million, compared to $21.470 million in the same period of 2024 [19] - Cash flows from investing activities showed a net cash provided of $78.359 million, contrasting with a net cash used of $52.652 million in the previous year [19] - Net cash provided by financing activities was $313.480 million, up from $173.108 million in the same period of 2024 [19]

Core Insights - Tucows Inc. reported a 10.1% increase in consolidated net revenue for Q2 2025, reaching $98.5 million compared to $89.4 million in Q2 2024, driven by strong performance across all business segments [3][8] - The company achieved a 6.2% increase in gross profit, totaling $22.1 million, attributed to margin gains from Wavelo and Tucows Domains, despite a decrease in gross margin from Ting due to a one-time lease adjustment [4][8] - Adjusted EBITDA grew by 37% to $12.6 million, reflecting improved operational efficiency and revenue growth across all segments [6][8] Financial Performance - Net loss for Q2 2025 decreased to $15.6 million, or $1.41 per share, compared to a net loss of $18.6 million, or $1.70 per share, in Q2 2024, indicating improved operational efficiency [5][8] - Adjusted net loss for Q2 2025 was $16.3 million, or $1.47 per share, compared to an adjusted net loss of $17.8 million, or $1.63 per share, in Q2 2024 [5][8] - Cash and cash equivalents at the end of Q2 2025 were $68.6 million, up from $55.0 million at the end of Q1 2025 and $52.2 million at the end of Q2 2024 [7][8] Business Segment Performance - Ting Internet Services generated revenue of $16.4 million, up from $14.6 million in Q2 2024, with gross profit decreasing due to a one-time lease expense [9][10] - Wavelo Platform Services reported revenue of $12.7 million, an increase from $10.5 million in Q2 2024, with gross profit also rising [10] - Tucows Domain Services achieved revenue of $67.6 million, compared to $62.4 million in Q2 2024, with gross profit increasing to $21.6 million [10]

Financial Performance - Q2 2025 - Total revenue for Q2 2025 increased by 7% year-over-year, reaching $103 million[20] - Clinical Solutions revenue increased significantly by 32% compared to Q2 2024[21] - Gross margin improved from 292% in Q2 2024 to 387% in Q2 2025[23] - Adjusted EBITDA improved from a loss of $26 million in Q2 2024 to a loss of $08 million in Q2 2025[26] - Free cash flow improved from a negative $30 million in Q2 2024 to a negative $23 million in Q2 2025[28] Revenue Breakdown - 2024 - Catalog products accounted for approximately 60% of total revenue in 2024[14, 15] - Custom products represented about 35% of total revenue in 2024, with biopharma contributing 70% of custom revenue and 25% of total revenue[14, 15] - Other revenue, including services and shipping, made up roughly 5% of total revenue in 2024[14, 15] Customer Migration and Spending - Customers purchasing GMP reagents spent 44 times more annually compared to catalog-only customers in 2024[17] - 58% of 2024 revenue came from custom and/or clinical accounts[17] - 27% of 2024 revenue was generated from Cell and Gene Therapy (CGT) customers[17] 2025 Outlook - The company estimates total revenue between $39 million and $42 million, representing a 7% year-over-year increase at the midpoint[41] - The company is targeting a free cash outflow of less than $12 million for 2025[41] - The company estimates an annualized revenue range of $50 million to $55 million to achieve Adjusted EBITDA break-even[41]

Core Viewpoint - Post Holdings, Inc. reported a mixed performance for the third fiscal quarter ended June 30, 2025, with net sales increasing slightly but challenges in specific segments, particularly in Post Consumer Brands, while raising its Adjusted EBITDA outlook for the fiscal year 2025 [4][10][30]. Financial Performance - Net sales for the third quarter were $1,984.3 million, a 1.9% increase from $1,947.7 million in the prior year, including $8.4 million from the acquisition of Potato Products of Idaho [4][10]. - Gross profit rose to $596.2 million, representing 30.0% of net sales, up from 29.6% in the prior year [4]. - Selling, general and administrative expenses decreased by 3.8% to $312.1 million, or 15.7% of net sales [5]. - Operating profit increased by 15.5% to $234.6 million compared to $203.2 million in the prior year [5]. - Net earnings were $108.8 million, a 9.0% increase from $99.8 million in the prior year, with diluted earnings per share rising to $1.79 from $1.53 [6]. Segment Performance - Post Consumer Brands experienced a 9.3% decline in net sales to $914.0 million, primarily due to a 10.3% decrease in volumes [14]. - Weetabix saw a slight increase in net sales to $137.9 million, aided by favorable foreign currency exchange rates, despite a 2.5% volume decrease [16]. - Foodservice segment net sales increased by 18.6% to $698.5 million, driven by distribution increases and the acquisition of PPI [18]. - Refrigerated Retail segment net sales rose by 9.1% to $233.9 million, with significant profit growth [21]. Adjusted EBITDA and Outlook - Adjusted EBITDA for the third quarter was $397.0 million, a 13.4% increase from $350.2 million in the prior year [7]. - The company raised its fiscal year 2025 Adjusted EBITDA outlook to a range of $1,500-$1,520 million, up from $1,460-$1,500 million [10][30]. Share Repurchases and Capital Expenditures - During the third quarter, Post repurchased 0.6 million shares for $62.1 million, with a remaining authorization of $231.4 million [27]. - Capital expenditures for fiscal year 2025 are expected to range between $450-$480 million, focusing on network optimization and facility expansions [31].

Core Insights - Aris Mining Corporation reported strong financial and operational results for Q2 2025, highlighting record adjusted EBITDA and net earnings, alongside significant cash growth [1][5][6]. Financial Performance - Total gold production reached 58,652 ounces, a 7% increase from Q1 2025 and a 19% increase from Q2 2024 [6]. - Gold sold totaled 61,024 ounces, up 12% from Q1 2025 and 23% from Q2 2024 [5][6]. - Record revenue of $200.2 million, representing a 30% increase from Q1 2025 and a 75% increase from Q2 2024 [5]. - Adjusted EBITDA was $98.7 million, up 48% from Q1 2025 and nearly triple compared to Q2 2024 [5][6]. - Adjusted net earnings were $47.8 million or $0.27 per share, the highest since the company's formation, up from $0.16 per share in Q1 2025 and $0.08 per share in Q2 2024 [5][6]. Operational Performance - Average realized gold price increased to $3,303 per ounce sold, compared to $2,855 in Q1 2025 and $2,313 in Q2 2024 [4][5]. - Segovia operations produced 51,527 ounces with an average gold grade of 9.85 g/t [4][6]. - The all-in sustaining cost (AISC) increased to $1,681 per ounce, primarily due to higher gold prices affecting costs related to materials and royalties [6]. Growth and Expansion - The commissioning of the second mill at Segovia in June 2025 is expected to enhance production in H2 2025, targeting annual production of 210,000 to 250,000 ounces this year and 300,000 ounces next year [12][19]. - Significant investments were made in growth capital, totaling $36.7 million, with $23.6 million allocated to the Marmato Bulk Mining Zone [5][12]. - The Marmato Bulk Mining Zone construction is progressing well, with first ore and production ramp-up expected in H2 2026 [12][19]. Cash Flow and Capital Structure - Cash balance increased to $310 million as of June 30, 2025, up from $240 million at the end of Q1 2025, driven by strong cash flow generation [5][12]. - The expiry of ARIS.WT.A warrants simplified the capital structure and eliminated a source of non-cash earnings volatility [5][12].

Company Overview - Golden Entertainment focuses on casino and branded tavern operations in Nevada[6,8] - The company owns real estate with excess land, providing potential development opportunities[11,12] - The company has an experienced management team aligned with shareholders[6] Market Position - Golden Entertainment operates 8 Nevada casinos with approximately 4,400 slots and 99 tables[7] - The company also operates 72 Nevada taverns with approximately 1,100 slots[7,26] - The company's loyalty program, True Rewards, includes over six million players[30] Financial Performance - As of June 30, 2025, the company's net debt was $385 million[32] - Since July 2023, the company has returned $216 million of capital to shareholders[33] - The company has $392 million in 1st lien term loans and $40 million drawn on a revolver as of June 30, 2025[36,37] Nevada Market - Nevada's total gaming Gross Gaming Revenue (GGR) in 2024 was $156 billion[17] - Las Vegas Strip GGR in 2024 was $88 billion, while Nevada locals GGR was $36 billion[17] - Las Vegas visitation reached 425 million in 2024[18]

HEPLISAV-B Performance and Market Outlook - HEPLISAV-B achieved a quarterly sales record of $92 million, a 31% increase year-over-year compared to $70 million in Q2'24[5] - HEPLISAV-B's total U S quarter-end market share reached approximately 45%, up from approximately 42% in Q2'24[5] - The U S adult Hepatitis B vaccine market is expected to peak at over $900 million by 2030, with HEPLISAV-B projected to reach at least 60% of the total U S market share[5, 25] - In 2024, the HEPLISAV-B total market share was ~$615M and is expected to increase from 44% in 2024 to at least 60% by 2030[25] Financial Highlights - The company's cash, cash equivalents, and marketable securities totaled $614 million as of June 30, 2025[7] - Adjusted EBITDA for FY 2025 is expected to be greater than $75 million[8] - Dynavax completed repurchases under the previously announced $200 million share repurchase program as of June 30, 2025[9] - Total revenues for Q2'25 were $95.4 million, a 29% increase from $73.8 million in Q2'24[53] Pipeline Development - The company expects to report top-line data results for the Shingles vaccine program in August 2025[10] - The U S DoD partnership provides approximately $30 million through 1H'27 to fund additional clinical & manufacturing activities for the Plague vaccine program[10] - The company plans to initiate a Phase 2 clinical trial for the Plague vaccine program in the second half of 2025[10]

Core Insights - American Healthcare REIT, Inc. reported strong second quarter results for 2025, leading to an increase in full-year guidance for Same-Store NOI growth and NFFO [1][3][12] Financial Performance - The Company achieved Same-Store NOI growth of 13.9% for Q2 2025 compared to Q2 2024, with significant contributions from the ISHC and SHOP segments, which grew by 18.3% and 23.0% respectively [4][5][6] - Reported GAAP net income attributable to controlling interest was $9.9 million, translating to $0.06 per diluted share for Q2 2025 [6][30] - Normalized Funds from Operations (NFFO) for Q2 2025 was reported at $0.42 per diluted share [6][32] Operational Highlights - The Company has seen a broad-based increase in demand across its operating portfolio, with occupancy rates improving significantly, particularly in independent and assisted living units [5][11] - The total portfolio Same-Store NOI growth guidance for the year ending December 31, 2025, has been increased to a range of 11.0% to 14.0% [6][12] Capital Markets Activity - During Q2 2025, the Company issued 5,451,577 shares of common stock through its ATM program, raising approximately $188.6 million [10][11] - The Company has closed on approximately $255 million of new investments year-to-date 2025 [6][10] Balance Sheet and Liquidity - As of June 30, 2025, the Company reported total consolidated indebtedness of $1.55 billion and total liquidity of approximately $733.5 million [9][28] - The Net Debt-to-Annualized Adjusted EBITDA improved to 3.7x from 4.5x as of March 31, 2025 [6][9] Future Outlook - The Company anticipates continued strong performance in the second half of 2025, driven by ongoing occupancy improvements and effective asset management strategies [5][11] - Full-year guidance for NFFO has been increased to a range of $1.64 to $1.68 per diluted share, reflecting improved expectations for NOI growth [6][12]

Core Viewpoint - Natural Grocers by Vitamin Cottage, Inc. reported strong third-quarter results for fiscal 2025, leading to an increase in its fiscal outlook for daily average comparable store sales growth and diluted earnings per share [2][19]. Financial Performance - Net sales for the third quarter of fiscal 2025 increased by $19.6 million, or 6.3%, to $328.7 million compared to the same period in fiscal 2024, driven by a $19.0 million increase in comparable store sales [3][7]. - Daily average comparable store sales grew by 7.4%, with a 4.8% increase in daily average transaction count and a 2.4% increase in daily average transaction size [3]. - Net income rose by 26.0% to $11.6 million, resulting in diluted earnings per share of $0.50, compared to $9.2 million and $0.40 per share in the third quarter of fiscal 2024 [8][7]. Operating Results - Gross profit for the third quarter increased by $7.9 million, or 8.8%, to $98.3 million, with a gross margin of 29.9%, up from 29.2% in the prior year [4]. - Operating income increased by 21.3% to $15.6 million, with an operating margin of 4.7%, compared to 4.2% in the third quarter of fiscal 2024 [8]. - Adjusted EBITDA for the third quarter was $24.4 million, a 10.1% increase from $22.2 million in the same quarter of fiscal 2024 [9][34]. Expense Management - Store expenses rose by 6.1% to $71.7 million, but as a percentage of net sales, they decreased to 21.8% from 21.9% in the prior year, indicating expense leverage [5]. - Administrative expenses increased by 14.7% to $10.9 million, with a rise in technology and compensation costs, leading to an increase in administrative expenses as a percentage of net sales to 3.3% from 3.1% [6][12]. Outlook - The company raised its fiscal 2025 outlook for daily average comparable store sales growth to a range of 7.25% to 7.75% and diluted earnings per share to $1.90 to $1.95 [19]. - The updated outlook for the number of new stores is now 2, down from a previous estimate of 3 to 4, while the number of relocations/remodels is updated to 3 [19]. Balance Sheet and Cash Flow - As of June 30, 2025, the company had $13.2 million in cash and cash equivalents, with no outstanding borrowings on its $72.5 million revolving credit facility [16]. - The company generated $39.7 million in cash from operations during the first nine months of fiscal 2025 [16]. Growth and Development - The company ended the third quarter with 169 stores across 21 states and has remodeled one store since June 30, 2025 [18].

Core Viewpoint - Biodesix, Inc. reported strong financial results for Q2 2025, with a revenue increase of 12% year-over-year, reaching $20.0 million, and reaffirmed its full-year revenue guidance of $80-85 million [1][6]. Financial Performance - Q2 2025 revenue was $20.0 million, a 12% increase compared to Q2 2024 [1][4]. - Gross profit margin for Q2 2025 was 80%, reflecting a 150-basis point improvement from the previous year [1][11]. - Development Services revenue grew by 53% year-over-year, reaching $2.1 million [5][20]. - Lung Diagnostic Testing revenue was $17.9 million, an 8% increase from the prior year, driven by an increase in total tests delivered [5][20]. - Adjusted EBITDA loss for Q2 2025 was $7.2 million, a 29% increase in loss compared to the same period last year [11][22]. Business Highlights - The sales team expanded to an average of 74 representatives, a 21% increase from the previous year [5]. - Primary care ordering of lung diagnostic tests increased over 100% compared to pre-pilot program levels in 2024 [5]. - The company achieved an all-time high in development services business dollars under contract, totaling $12.5 million, up 54% year-over-year [5]. - Digital ordering initiatives saw a 63% increase over the prior year [5]. - The company reached patient enrollment requirements for its ALTITUDE trial in July 2025 [5]. Future Outlook - The company is positioned to achieve Adjusted EBITDA positivity in Q4 2025, supported by sales team expansion and operational effectiveness [2]. - Biodesix maintains confidence in achieving its full-year revenue guidance of $80-85 million, indicating a focus on sustainable long-term growth [2][6].